Abstract
Various peripheral immune cell populations have previously been implicated as potential biomarkers for response to immune checkpoint inhibition, although with inconsistent results between studies. The single-arm phase II trial SAKK 16/14 confirmed the efficacy of perioperative treatment with the andi-PD-L1 antibody durvalumab in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) with a clinically meaningful benefit compared to neoadjuvant chemotherapy alone. To evaluate the impact of treatment on the immune system, we comprehensively profiled immune cell populations derived from SAKK16/14 patients’ peripheral blood mononuclear cells (PBMCs) by mass cytometry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
